Purpose of review Antiphospholipid syndrome (APS) is a leading acquired cause of thrombosis and pregnancy loss. Upon diagnosis (which is unlikely to be made until at least one morbid event has occurred), anticoagulant medications are typically prescribed in an attempt to prevent future events. This approach is not uniformly effective and does not prevent associated autoimmune and inflammatory complications. The goal of this review is to update clinicians and scientists on mechanistic and clinically relevant studies from the past 18 months, which have especially focused on inflammatory aspects of APS pathophysiology.
INTRODUCTION
Vascular complications, including thrombotic events, are among the leading causes of morbidity and mortality in lupus. Antiphospholipid antibodies (aPL), a major driver of thrombosis risk, are present in up to one-third of lupus patients. When aPL are associated with certain clinical complications (either thrombotic or obstetric), a diagnosis of antiphospholipid syndrome (APS) is assigned (Table 1 ) [1] . Beyond lupus-associated APS, approximately half of APS cases will be diagnosed as a standalone syndrome (i.e., primary APS) [2] .
APS is a leading acquired cause of thrombosis and pregnancy loss, with an estimated prevalence of one in 2000 [3] . Framing this risk another way, aPL can be detected on the order of 10% of the time in the setting of certain events, including pregnancy morbidity, stroke, myocardial infarction, and deep venous thrombosis [4] . Emphasizing the systemic nature of APS, the diagnosis also portends risk for cytopenias (especially hemolytic anemia and thrombocytopenia), mitral and aortic valve lesions, seizure disorder, accelerated cognitive decline, and nephropathy in the form of thrombotic microangiopathy [5] . The approach to treatment is typically with anticoagulant drugs, which are not uniformly effective in preventing recurrent aPL-mediated thrombosis and pregnancy loss and offer insufficient protection against the varied 'noncriteria' manifestations of APS. Indeed, 44% of 'triplepositive' APS patients (positive testing for anticardiolipin, antibeta-2-glycoprotein I, and lupus anticoagulant) will develop recurrent thrombosis over a 10-year follow-up period (even with the majority being prescribed anticoagulants) [6] . Furthermore, at least 20% of obstetric APS patients have adverse outcomes in spite of therapy with aspirin and low-molecular-weight heparin [7] .
Despite its high prevalence and potential for devastating morbidity, APS pathophysiology has yet to be fully defined. APS was historically viewed as a coagulation problem; however, clinical observations and basic science discoveries are increasingly highlighting a more multifaceted syndrome with an associated (and perhaps even central) inflammatory component [8] . Herein, we will discuss recent discoveries over the past 18 months, which have continued to increase our understanding of APS pathophysiology. We will also discuss how this improved basic understanding may translate to new and repurposed therapeutics for APS (Table 2) .
CELL ACTIVATION AND SIGNALING PATHWAYS: NEW CONCEPTS
Understanding the cellular signaling pathways that mediate APS pathogenesis has remained somewhat elusive, at least partially the consequence of study heterogeneity. Studies have utilized different types of aPL (monoclonal vs. patient-derived; protein cofactor-dependent vs. cofactor-independent) and have focused on a variety of cellular targets (endothelial cells, platelets, monocytes, neutrophils, trophoblast cells, etc.).
Many pathogenic antibodies in APS do not target phospholipids themselves, but rather phospholipid-binding protein cofactors. The best characterized of these cofactors is beta-2 glycoprotein I (b 2 GPI), a lipid-binding protein present at high levels in plasma [22, 23] , albeit with largely unknown endogenous function. The mechanistic schema is that anti-b 2 GPI antibodies potentiate thrombosis by engaging b 2 GPI protein that has been recruited to cell surfaces -and thereby promote cell activation [24] [25] [26] . The mechanisms by which antib 2 GPI antibodies activate cells have been recently reviewed [27] , with roles especially suggested for the cell surface proteins annexin A2, apolipoprotein E receptor 2 (ApoER2), Toll-like receptor 2 (TLR2), and TLR4 [27] .
KEY POINTS
Current standard-of-care therapy for APS does not explicitly target inflammatory aspects of APS pathophysiology.
A better understanding of intercellular and intracellular signaling pathways in APS has revealed potential drug targets (i.e., interferons, phosphoinositide 3-kinase, etc.).
In addition to the well established cellular mediators of APS pathogenesis (endothelial cells, platelets, etc.), there is emerging interest in the contribution of myeloidlineage cells. The role of neutrophil extracellular trap release, in particular, warrants further study.
Complement activation and deposition continue to be recognized for their role in APS pathogenesis. Activity of this pathway may be mitigated by several medications, including rivaroxaban and hydroxychloroquine.
Adjuvant therapeutics, including statins and hydroxychloroquine, have the potential to improve APS pregnancy outcomes, based upon animal studies and small clinical trials. mice are relatively resistant to thrombosis when confronted with aPL. More recently, it has been revealed that ApoER2 may play an important role in obstetric APS [29] . Specifically, Ulrich et al. [29] demonstrated enhanced placental trophoblast cell proliferation and migration in vitro when aPL engage b 2 GPI/ApoER2 complexes on the trophoblast cell surface. Extending these studies to an in-vivo model of aPL-mediated pregnancy loss, they demonstrated protection in ApoER2 À/À mice [29] . In another recent study, Mineo et al. [30 & ] developed a mAb against b 2 GPI that prevents pathogenic aPL binding, thereby protecting against aPL-mediated cell activation. The antibody attenuated the association of b 2 GPI with ApoER2, thereby normalizing endothelial and trophoblast cell function in vitro, as well as preventing thrombosis and fetal loss in vivo [30 & ]. Although further study is clearly needed, the intersection of aPL, b 2 GPI, and ApoER2 warrants investigation as a potential therapeutic target in patients.
As neither b 2 GPI itself, nor some b 2 GPI 'receptors' such as annexin A2, have a cytoplasmic domain to mediate signaling, there has been interest in additional partner proteins that may convey activating signals to the cytoplasm. On this front, particular attention has been given to the cellsurface TLRs, TLR2 and TLR4. In mouse models, TLR4 deletion protects against venous and arterial thrombosis in some [31] [32] [33] , but not all [34 & ], studies (it is worth pointing out that the latter study utilized cofactor-independent aPL). Studies of obstetric APS have also yielded mixed results with an older study demonstrating no role for TLR4 in an in-vivo model of pregnancy loss [35] . In contrast, Azuma et al. [36] recently suggested that, at least in-vitro, TLR2 and TLR4 facilitate inflammatory cytokine production by trophoblast cells in response to anti-b 2 GPI antibodies.
Signaling pathways downstream of the aforementioned receptors, at least as they relate to APS pathogenesis, remain incompletely understood. Terrisse et al. [37 & ] recently investigated downstream signaling pathways by which aPL (especially IgG isolated from APS patients) activate platelets. The authors demonstrated that aPL potentiate ex-vivo platelet activation through surface glycoprotein Iba (the platelet receptor for von Willebrand factor) and TLR2, by a mechanism involving class IA phosphoinositide 3-kinase (PI3K) a and b isoforms [37 & ]. One downstream consequence of PI3K signaling is activation of the serine/threonine kinase Akt, a pathway that supports cell survival, proliferation, and migration [37 & ]. Indeed, PI3K inhibitors, which are being explored as potential drug targets in other contexts [38] , are effective at preventing aPL-mediated platelet activation [37 & ]. Interestingly, another study has suggested that Akt activation is a downstream consequence of trophoblast cell activation by aPL [29] .
Beyond the engagement of aPL with cell surfaces, a recent report by Wu et al. APS patients No prospective studies in APS, but protects in postoperative setting [12] No studies in APS, but protects in the general population [13] Efficacy may be similar to warfarin in carefully-selected patients (though further study is needed) [ . They also speculate that these vesicles may be a mechanism for delivery of specific and functionally-relevant micro-RNA, though this hypothesis requires further study.
THE VESSEL WALL: ENDOTHELIAL PROGENITORS AND INTERFERONS
Our group recently looked 'upstream' of endothelial cells, asking whether a deficiency in reparative, circulating endothelial progenitors might contribute to defective maintenance and health of the endothelium over time. Indeed, a deficiency in the number and function of such progenitors is a well recognized aspect of both lupus and rheumatoid arthritis (RA) [40] . We found that primary APS patients have a reduction in functional endothelial progenitors, which was interestingly not dependent upon patient IgG; rather, we discovered a type I interferon signature in the APS patients, abrogation of which could restore normal progenitor function ], who found that approximately 50% of primary APS patients have a type I interferon signature, which was less likely to be present in patients taking either hydroxychloroquine or statins. Interestingly, they also found that the interferon signature correlated with expansion of 'intermediate' and 'nonclassical' monocytes (which have been previously linked to cardiovascular disease in lupus and RA) [20 && ]. How these monocytes intersect with endothelial progenitors [42] , and whether there is a role for anti-interferon therapy in APS [43] , are questions that deserve further consideration.
One potential consequence of endothelial cell (and progenitor) dysfunction is atherosclerosis, an accelerated version of which is a well known complication of lupus [44] , and which has also been reported in APS [45, 46] . The recent work of Benagiano et al. has examined the role of T H 1 specific inflammatory responses to b 2 GPI in established atherosclerotic lesions of primary APS patients. Their work demonstrated that plaque-derived, b 2 GPI-specific CD4þ T-lymphocytes facilitate perforin-mediated and Fas ligand-mediated cytotoxicity, pointing to a role for these autoreactive T cells in plaque destabilization (and potentially the arterial thrombotic events that are known to occur at higher frequency in APS) [47 && ]. They also demonstrated that b 2 GPI can induce proliferation of (and IFN-g expression by) plaque-derived T-cell clones [47 && ]. Furthermore, these T cells amplify monocyte responses, such as the production of tissue factor (TF) and matrix metalloproteinases, which can be inhibited with an anti-IFN-g antibody [47 && ].
MYELOID-LINEAGE CELLS: NEUTROPHIL EXTRACELLULAR TRAPS AND MONOCYTE NOX2
The role of neutrophils in APS pathogenesis has only recently been investigated. This interest was precipitated by emerging descriptions of neutrophils as mediators of both pathologic clotting and autoimmune diseases [48, 49] . In particular, neutrophil extracellular traps (NETs) (extracellular chromatinbased structures released by activated neutrophils) have been described as triggers of autoimmunity and tissue damage, as well as important instigators of thrombosis [50] . ]. In parallel to our work, van den Hoogen et al. [53] reported increased levels of circulating 'low-density granulocytes' or LDGs in patients with primary APS. This proinflammatory subset of neutrophils has been well characterized in systemic lupus erythematosus and other autoimmune disorders, in which they are reported to release NETs in exaggerated fashion [54] . Whether LDGs are important sources of NETs in APS awaits further study [55] .
The in-vivo relevance of NETs was recently confirmed by our group in a mouse model of APS. In this model, IgG from triple-positive APS patients potentiated venous thrombosis in mice that had been subjected to flow restriction in the inferior vena cava by a standard surgical stenosis [ ] published an elegant study demonstrating that cofactorindependent aPL could similarly potentiate thrombosis in an inferior vena cava flow-restriction model. Their interesting work found a major role for leukocyte activation in thrombus formation, which could be abrogated by deletion of NOX2 (the catalytic subunit of NADPH oxidase) from bone marrowderived cells. Although the authors' primary interest was in monocyte NOX2 and its role in TF expression, there is also a well accepted role for neutrophil NOX2 in NET formation [57] . Further studies may assess the role of these cofactor-independent antiphospholipid antibodies in inducing NET release in vitro and in vivo.
COMPLEMENT: AT THE INTERSECTION OF COAGULATION AND INFLAMMATION IN ANTIPHOSPHOLIPID SYNDROME
Animal models of APS have supported a role for complement activation in both thrombotic events and pregnancy loss [58, 59] . Studies in APS patients have demonstrated smoldering activity of the complement cascade [60] [61] [62] , whereas a recent case report revealed deposition of b 2 GPI protein, IgG, and complement components C1q, C4, C3, and C5b-9 at the endothelial surface of an occluded artery in an APS patient [63] . Furthermore, this patient, who had suffered recurrent arterial occlusions, was successfully revascularized while under treatment with eculizumab, a terminal complement inhibitor [63] .
In lupus, antibodies to C1q (a complex that initiates the complement cascade in response to immune complexes) amplify complement activation and strongly correlate with certain clinical manifestations such as proliferative nephritis [64] . Oku et al. [65] recently investigated these antibodies in primary APS patients, demonstrating that 36% of patients had detectable anti-C1q (compared with 55% of lupus patients). Interestingly, titers of antiC1q were significantly higher in patients with refractory APS [65] .
Rivaroxaban, a direct factor Xa inhibitor, has recently been considered as an alternative agent to vitamin K antagonists in APS. The first randomized, prospective study investigating use of rivaroxaban in APS (RAPS trial) was recently published. In patients with a history of venous thromboembolism (who had already demonstrated stable disease on warfarin), both warfarin and rivaroxaban prevented new thrombotic events for 210 days in every study patient [14 && ]. Bleeding events and overall adverse events were also similar between the groups [14 && ]. Although a full recounting of this important trial is beyond the scope of this brief review, we would refer you to a detailed comment on the topic [66] . Related to our discussion of the complement pathway, a post-hoc analysis of the RAPS trial revealed that, prior to randomization, APS patients had significantly higher markers 
REPURPOSING MEDICATIONS: STATINS AND HYDROXYCHLOROQUINE AS ADJUVANT THERAPIES IN ANTIPHOSPHOLIPID SYNDROME?
HMG-CoA reductase inhibitors (or statins) have long been recognized to have pleotropic antiinflammatory effects supportive of vascular health, including reductions in inflammation, oxidative stress, and coagulation [67] . Clinically, statins appear to reduce the risk of venous thromboembolism in the general population [13] . In mouse models of APS, statins mitigate aPL-mediated thrombotic events and fetal death [11, 16] . Furthermore, when administered to APS patients, statins decrease both prothrombotic and proinflammatory biomarkers [68] .
The standard of care for managing pregnancy complications in APS is the administration of lowdose aspirin and low-molecular-weight heparin (the latter at either prophylactic or therapeutic doses, depending on the patient's thrombosis history) [69, 70] . However, as detailed in recent review articles [69, 70] , pregnancy complications in APS are often not based in frank placental thrombosis, but rather spiral artery vasculopathy, as well as acute and chronic inflammation -with increased infiltration of inflammatory cells and deposition of complement in the placentae of women with APS [71] [72] [73] . Lefkou et al. ]. There was a remarkable therapeutic benefit, with all the patients receiving pravastatin delivering healthy infants at 34-38 weeks [18 && ]. In contrast, the 10 patients who remained on standard therapy had three stillbirths at 25-26 weeks and seven preterm Cesarean sections (resulting in two fetal deaths) [18 && ]. Hydroxychloroquine (which is nowadays prescribed to essentially all patients with lupus) was utilized in the 1970s to reduce the risk of venousthromboembolism in postoperative patients [12] . In the 1990s, hydroxychloroquine was demonstrated to protect against aPL-mediated thrombosis in mice [9] . Furthermore, there have been hints of a reduction in thrombosis risk in lupus patients taking hydroxychloroquine, as compared with those who are not [74, 75] . Mechanistically, a recent study demonstrated that hydroxychloroquine inhibits the translocation of monocyte NOX2 to the endosome in response to stimulants such as TNFa, IL-1b, and aPL [10 && ]. This was accompanied by mitigation of aPL-induced, NOX2-mediated thrombus formation in vivo [10 && ]. As the related drug chloroquine has been shown to antagonize NET release [21] , further studies should continue to explore the intersection of hydroxychloroquine, activated monocytes/neutrophils, and APS.
Given its excellent safety profile in pregnancy [76] , and its nearly standard-of-care application in lupus pregnancies, hydroxychloroquine has been increasingly considered as adjuvant therapy in APS pregnancies. Indeed, recent retrospective studies have suggested a beneficial effect of hydroxychloroquine in APS pregnancies [7, 17] 
CONCLUSION
Since its description in the 1980s, APS has been managed primarily with anticoagulant medications. These medications are not universally protective against subsequent thrombotic events and pregnancy loss and have little proven track record in treating 'noncriteria' manifestations of APS such as cytopenias and cardiac valvular disease. Basic science studies continue to refine the signaling pathways, activated cells, and noncellular effectors critical for APS pathogenesis (Fig. 1) . In addition to a search for novel therapeutics, established medications such as statins and hydroxychloroquine are receiving increasing interest as adjuvant therapies. In the near future, we hope to see more well designed clinical trials with both mechanistic and clinical endpoints.
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